At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Market Closed 09-04 16:00:00 EDT
1.16
-0.54
-31.76%
盘后1.19
+0.03+2.59%
19:59 EDT
High1.56Low1.16Vol15.51M
Open1.50D1 Closing1.70Amplitude23.24%
Mkt Cap1.72MTradable Cap1.71MTotal Shares1.49M
T/O28.92MT/O Rate1,051.01%Tradable Shares1.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Clearmind Medicine Agrees to Buy 51% of Charging Robotics for $2.5 Million
Reuters  ·  09-04 19:32
Clearmind Medicine Agrees to Buy 51% of Charging Robotics for $2.5 Million
Clearmind Medicine - to Extend $1.50 Mln Loan to Charging Robotics at 4% Interest
THOMSON REUTERS  ·  09-04 19:32
Clearmind Medicine - to Extend $1.50 Mln Loan to Charging Robotics at 4% Interest
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
THOMSON REUTERS  ·  09-04 19:32
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Clearmind Medicine Sets USD 1 Conversion Price for USD 696,079.50 in Notes into Common Shares
Reuters  ·  09-03
Clearmind Medicine Sets USD 1 Conversion Price for USD 696,079.50 in Notes into Common Shares
Clearmind Medicine Starts Phase IIa CMND-100 Trial in Alcohol Use Disorder Patients
Reuters  ·  09-01
Clearmind Medicine Starts Phase IIa CMND-100 Trial in Alcohol Use Disorder Patients
Clearmind Reaches Key Milestone: Cmnd-100 Phase Iia NOW Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
THOMSON REUTERS  ·  09-01
Clearmind Reaches Key Milestone: Cmnd-100 Phase Iia NOW Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination
TIPRANKS  ·  08-24
SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination
Clearmind Medicine Says US Publishes MDMA-PEA Patent Application for PTSD Treatment
Reuters  ·  08-24
Clearmind Medicine Says US Publishes MDMA-PEA Patent Application for PTSD Treatment
Clearmind Advances Mdma-N-Acylethanolamines Ip for the Treatment of Ptsd Amid Rising U.S. Federal Support for Psychedelic Innovation
THOMSON REUTERS  ·  08-24
Clearmind Advances Mdma-N-Acylethanolamines Ip for the Treatment of Ptsd Amid Rising U.S. Federal Support for Psychedelic Innovation
Clearmind Advances CMND-100 into Alcohol Use Disorder Patients After Phase I/II Safety Milestone
Reuters  ·  08-13
Clearmind Advances CMND-100 into Alcohol Use Disorder Patients After Phase I/II Safety Milestone
Clearmind Advances Cmnd-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
THOMSON REUTERS  ·  08-13
Clearmind Advances Cmnd-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
Clearmind Medicine Announces Positive Permeation Results for Intranasal Meai Formulation
Reuters  ·  08-11
Clearmind Medicine Announces Positive Permeation Results for Intranasal Meai Formulation
Clearmind Medicine reports MEAI development program permeation study results
TIPRANKS  ·  08-11
Clearmind Medicine reports MEAI development program permeation study results
Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Formulation Study
Reuters  ·  08-11
Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Formulation Study
Clearmind Medicine - Intranasal Meai Shows Enhanced Nasal Retention Without Compromising Permeation
THOMSON REUTERS  ·  08-11
Clearmind Medicine - Intranasal Meai Shows Enhanced Nasal Retention Without Compromising Permeation
Clearmind Medicine reports DSMB approves advancing Phase I/II AUD study
TIPRANKS  ·  08-06
Clearmind Medicine reports DSMB approves advancing Phase I/II AUD study
Clearmind Advances CMND-100 Alcohol Use Disorder Trial into Patient Testing After Phase I Safety Readout
Reuters  ·  08-06
Clearmind Advances CMND-100 Alcohol Use Disorder Trial into Patient Testing After Phase I Safety Readout
Clearmind Reaches Key Clinical Trial Milestone as Dsmb Unanimously Clears Progression in AUD Study
THOMSON REUTERS  ·  08-06
Clearmind Reaches Key Clinical Trial Milestone as Dsmb Unanimously Clears Progression in AUD Study
Clearmind Signs LOI to Buy 51% Stake in EV Wireless Charging Firm for $2.5 Million
Reuters  ·  08-03
Clearmind Signs LOI to Buy 51% Stake in EV Wireless Charging Firm for $2.5 Million
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
THOMSON REUTERS  ·  08-03
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

Introduction

Company Name.
Clearmind Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Issue price:
--